全文获取类型
收费全文 | 383篇 |
免费 | 24篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 53篇 |
口腔科学 | 12篇 |
临床医学 | 28篇 |
内科学 | 108篇 |
皮肤病学 | 7篇 |
神经病学 | 52篇 |
特种医学 | 17篇 |
外科学 | 40篇 |
综合类 | 1篇 |
预防医学 | 17篇 |
眼科学 | 4篇 |
药学 | 31篇 |
肿瘤学 | 29篇 |
出版年
2023年 | 2篇 |
2022年 | 8篇 |
2021年 | 8篇 |
2019年 | 4篇 |
2018年 | 5篇 |
2017年 | 6篇 |
2016年 | 8篇 |
2015年 | 11篇 |
2014年 | 13篇 |
2013年 | 16篇 |
2012年 | 28篇 |
2011年 | 25篇 |
2010年 | 20篇 |
2009年 | 15篇 |
2008年 | 26篇 |
2007年 | 21篇 |
2006年 | 30篇 |
2005年 | 30篇 |
2004年 | 18篇 |
2003年 | 24篇 |
2002年 | 13篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1995年 | 2篇 |
1993年 | 2篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 1篇 |
1971年 | 3篇 |
1970年 | 6篇 |
1969年 | 2篇 |
1968年 | 5篇 |
1967年 | 2篇 |
1966年 | 1篇 |
1965年 | 3篇 |
1956年 | 1篇 |
1955年 | 2篇 |
排序方式: 共有407条查询结果,搜索用时 15 毫秒
41.
Naumann A Söderhäll C Fölster-Holst R Baurecht H Harde V Müller-Wehling K Rodríguez E Ruether A Franke A Wagenpfeil S Novak N Mempel M Kalali BN Allgaeuer M Koch J Gerhard M Melén E Wahlgren CF Kull I Stahl C Pershagen G Lauener R Riedler J Doekes G Scheynius A Illig T von Mutius E Schreiber S Kere J Kabesch M Weidinger S 《The Journal of allergy and clinical immunology》2011,127(5):156-1194
42.
Sonja C. Lück Annika C. Russ Juan Du Verena Gaidzik Richard F. Schlenk Jonathan R. Pollack Konstanze Döhner Hartmut Döhner Lars Bullinger 《British journal of haematology》2010,148(6):925-937
Core binding factor (CBF) leukaemias, characterized by either inv(16)(p13.1q22) or t(8;21)(q22;q22), constitute acute myeloid leukaemia (AML) subgroups with favourable prognosis. However, 40–50% of patients relapse, emphasizing the need for risk‐adapted treatment approaches. In this regard, studying secondary genetic aberrations, such as mutations of the KIT gene, is of great interest, particularly as they can be targeted by receptor tyrosine kinase inhibitors (TKI). However, so far little is known about the biology underlying KIT‐mutated CBF leukaemias. We analysed gene expression profiles of 83 CBF AML cases with known KIT mutation status in order to gain novel insights in KIT‐mutated CBF pathogenesis. KIT‐mutated cases were characterized by deregulation of genes belonging to the NFkB signalling complex suggesting impaired control of apoptosis. Notably, a subgroup of KIT wildtype cases was also characterized by the KIT mutation signature due to yet unknown aberrations. Our data suggest that this CBF leukaemia subgroup might profit from TKI therapy, however, the relevance of the KIT mutation‐associated signature remains to be validated prior to clinical implementation. Nevertheless, the existence of such a signature supports the notion of relevant biological differences in CBF leukaemia and might serve as diagnostic tool in the future. 相似文献
43.
44.
Plaschke K von Haken R Scholz M Engelhardt R Brobeil A Martin E Weigand MA 《Intensive care medicine》2008,34(3):431-436
45.
Toni Luise Meister Yannick Brüggemann Maximilian K. Nocke Rainer G. Ulrich Jonas Schuhenn Kathrin Sutter Andr Gmer Verian Bader Konstanze F. Winklhofer Ruth Broering Lieven Verhoye Philip Meuleman Florian W. R. Vondran Charline Camuzet Laurence Cocquerel Daniel Todt Eike Steinmann 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(34)
Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and is the leading cause of enterically transmitted viral hepatitis worldwide. Ribavirin (RBV) is currently the only treatment option for many patients; however, cases of treatment failures or posttreatment relapses have been frequently reported. RBV therapy was shown to be associated with an increase in HEV genome heterogeneity and the emergence of distinct HEV variants. In this study, we analyzed the impact of eight patient-derived open reading frame 2 (ORF2) single-nucleotide variants (SNVs), which occurred under RBV treatment, on the replication cycle and pathogenesis of HEV. The parental HEV strain and seven ORF2 variants showed comparable levels of RNA replication in human hepatoma cells and primary human hepatocytes. However, a P79S ORF2 variant demonstrated reduced RNA copy numbers released in the supernatant and an impairment in the production of infectious particles. Biophysical and biochemical characterization revealed that this SNV caused defective, smaller HEV particles with a loss of infectiousness. Furthermore, the P79S variant displayed an altered subcellular distribution of the ORF2 protein and was able to interfere with antibody-mediated neutralization of HEV in a competition assay. In conclusion, an SNV in the HEV ORF2 could be identified that resulted in altered virus particles that were noninfectious in vitro and in vivo, but could potentially serve as immune decoys. These findings provide insights in understanding the biology of circulating HEV variants and may guide development of personalized antiviral strategies in the future.Despite its rising global prevalence, hepatitis E is a disease that is mostly overlooked. Every year, more than 44,000 people die as a result of ∼20 million infections worldwide (1). Healthy individuals usually display no or only mild symptoms of viral hepatitis, such as fever, nausea, vomiting, and abdominal pain (2), while patients with preexisting liver disease, pregnant women, and immunocompromised individuals suffer from liver cirrhosis and liver failure (3). Pregnant women additionally present with increased mortality rates of >25% (4). Despite those liver-associated problems, there are also extrahepatic manifestations, such as hematopoietic disease, neurological disorders, and renal injury (5–9). The underlying agent, hepatitis E virus (HEV), is classed within the species of Paslahevepirus balayani (10), formerly known as Orthohepevirus A, which includes isolates from human, swine, wild boar, rat, and other mammals. HEV is a quasienveloped virus existing as both enveloped and non-enveloped particles (11, 12). To date, eight distinct genotypes (GT) of this species of the single-stranded RNA virus have been described (13), which display similar genomic structures. The positive orientated HEV genome is organized in three main open reading frames (ORF1 to ORF3) with a total length of 7.2 kb. Nonstructural proteins forming the HEV replicase complex, such as the RNA-dependent RNA polymerase (RdRp), RNA helicase, or methyltransferase, are encoded by ORF1, while the viral capsid protein is encoded by ORF2. During the HEV replication cycle, HEV produces at least three forms of ORF2 protein: infectious ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c) protein (14). The ORF2i protein is the structural component of infectious particles that is likely derived from the assembly of the intracellular ORF2 (ORF2intra) protein form. In contrast, ORF2g and ORF2c protein are not associated with infectious virions, but secreted in large amounts and are the most abundant antigens detected in patient sera (14). ORF3 encodes for a functional ion channel required for assembly and release of infectious particles by interacting with a variety of host factors (15).In immunocompetent patients, acute hepatitis E usually does not involve antiviral therapy; however, chronically infected and immunocompromised patients often require clinical intervention to clear the infection. Antiviral therapies include pegylated interferon (16–18), successfully implemented for many virus infections, and sofosbuvir (19, 20), a direct acting antiviral against hepatitis C virus, both of which have not yet been systematically evaluated in the context of HEV therapy. Recent studies have investigated the antiviral potential of silvestrol (21), zinc salts (22), and other possible drug candidates in vitro [reviewed in detail by Kinast et al. (23)], but the findings remain to be clinically validated. Lacking specific treatment options, the broad antiviral ribavirin (RBV) (24) is frequently used off-label. However, RBV therapy is often discontinued due to adverse side effects and is only effective in ∼80% of patients, implying that 20% of treated patients remain viremic (25). RBV treatment is specifically contraindicated in pregnant women and can give rise to variants such as G1634R, as well as other amino acid substitutions within the ORF1-encoded polyprotein, potentially contributing to treatment failure and poor clinical long-term outcomes (26–28). In this context, we recently identified viral populations of HEV harboring variations in the capsid-encoding ORF2 region during RBV therapy. With the use of an efficient HEV cell-culture model system, we characterized the impact of these ORF2 variants in the HEV replication cycle. 相似文献
46.
Felicitas Thol Michaela Scherr Aylin Kirchner Rabia Shahswar Karin Battmer Sofia Kade Anuhar Chaturvedi Christian Koenecke Michael Stadler Uwe Platzbecker Christian Thiede Thomas Schroeder Guido Kobbe Gesine Bug Oliver Ottmann Wolf-Karsten Hofmann Nicolaus Kr?ger Walter Fiedler Richard Schlenk Konstanze D?hner Hartmut D?hner Jürgen Krauter Matthias Eder Arnold Ganser Michael Heuser 《Haematologica》2015,100(4):e122-e124
47.
48.
BackgroundA new tablet formulation containing 0.02 mg ethinylestradiol/3 mg drospirenone/0.451 mg levomefolate calcium (calcium salt containing 0.416 mg L-5-methyltetrahydrofolate) was assessed for bioequivalence compared to the approved oral contraceptive (OC) tablet containing identical amounts of ethinylestradiol and drospirenone and to a tablet containing 0.451 mg levomefolate calcium.Study DesignForty-four subjects received in an intraindividual crossover design single doses of the new tablet formulation or the established ethinylestradiol/drospirenone tablet or the levomefolate calcium tablet.ResultsBioequivalence was demonstrated for ethinylestradiol, drospirenone and L-5-methyltetrahydrofolate (active moiety of levomefolate calcium) between the investigated tablet formulations. The geometric mean ratios of the AUC(0–tlast) and Cmax values for all three compounds and their 90% confidence intervals were well within the 80%–125% range generally accepted to demonstrate bioequivalence.ConclusionThe rate and extent of absorption of ethinylestradiol and drospirenone were not affected by the concomitant administration of levomefolate calcium and vice versa. 相似文献
49.
BackgroundThis study investigated the effects of adding levomefolate calcium 0.451 mg (the calcium salt of L-5-methyltetrahydrofolate; Metafolin®) to an oral contraceptive containing ethinylestradiol (EE) 20 mcg/drospirenone (drsp) 3 mg on folate levels in healthy women seeking contraception.Study DesignIn this randomized, double-blind, multicenter US-based study, women (18–40 years) received 24 weeks (six cycles) of EE/drsp/levomefolate calcium or EE/drsp for 24 days followed by 4 days of levomefolate calcium alone or placebo, respectively. The primary efficacy variables were red blood cell (RBC) and plasma folate levels at 24 weeks.ResultsAt week 24, increases from baseline in mean RBC (990 ± 390 nmol/L to 1406 ± 440 nmol/L) and plasma folate (45.0 ± 17.6 nmol/L to 60.8 ± 19.9 nmol/L) levels were observed in women who received EE/drsp/levomefolate calcium [per protocol set (n=262); all values are displayed as mean ± standard deviation]. In contrast, marginal fluctuations were observed with EE/drsp (p<.0001 for between-treatment differences at week 24).ConclusionClinically significant increases in folate status were observed with EE/drsp/levomefolate calcium compared with EE/drsp alone in US women of childbearing age. 相似文献
50.
CSF flow measurement in syringomyelia 总被引:11,自引:0,他引:11
Brugières P Idy-Peretti I Iffenecker C Parker F Jolivet O Hurth M Gaston A Bittoun J 《AJNR. American journal of neuroradiology》2000,21(10):1785-1792
BACKGROUND AND PURPOSE: CSF circulation has been reported to represent a major factor in the pathophysiology of syringomyelia. Our purpose was to determine the CSF flow patterns in spinal cord cysts and in the subararachnoid space in patients with syringomyelia associated with Chiari I malformation and to evaluate the modifications of the flow resulting from surgery. METHODS: Eighteen patients with syringomyelia were examined with a 3D Fourier encoding velocity imaging technique. A prospectively gated 2D axial sequence with velocity encoding in the craniocaudal direction in the cervical region was set at a velocity of +/- 10 cm/s. Velocity measurements were performed in the larger portion of the cysts and, at the same cervical level, in the pericystic subarachnoid spaces. All patients underwent a surgical procedure involving dural opening followed by duroplasty. Pre- and postoperative velocity measurements of all patients were taken, with a mean follow-up of 10.2 months. We compared the velocity measurements with the morphology of the cysts and with the clinical data. Spinal subarachnoid spaces of 19 healthy subjects were also studied using the same technique. RESULTS: A pulsatile flow was observed in syrinx cavities and in the pericystic subarachnoid spaces (PCSS). Preoperative maximum systolic cyst velocities were higher than were diastolic velocities. A systolic velocity peak was well defined in all cases, first in the cyst and then in the PCSS. Higher systolic and diastolic cyst velocities are observed in large cysts and in patients with a poor clinical status. After surgery, a decrease in cyst volume (evaluated on the basis of the extension of the cyst and the compression of the PCSS) was observed in 13 patients. In the postoperative course, we noticed a decrease of systolic and diastolic cyst velocities and a parallel increase of systolic PCSS velocities. Diastolic cyst velocities correlated with the preoperative clinical status of the patients and, after surgery, in patients with a satisfactory foraminal enlargement evaluated on the basis of the visibility of the cisterna magna. CONCLUSION: CSF flow measurement constitutes a direct evaluation for the follow-up of patients with syringomyelic cysts. Diastolic and systolic cyst velocities can assist in the evaluation of the efficacy of surgery. 相似文献